Ovarian cancer trial to continue recruitment.

Eastland's under the tongue, Bionomics disrupts further, Novogen adds on and Mesoblast's arthritic sheep.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

A recently completed phase I clinical trial of biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 has shown rapid absorption indicating its potential as an oral therapy, according to the company.

The Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report.

Cancer drug developer Novogen's (ASX:NRT, Nasdaq:NVGN) revenue was down 10 per cent for the half year to December 31, 2005 compared with the previous corresponding period, due to a decrease in sales of its over-the-counter (OTC) natural products for menopause following a resurgence in rival prescribed drugs.

Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, has appointed Dr Reinhard Koenig as CEO and president.

Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market.

Australian biotech stocks underperformed both the All Ordinaries and the Nasdaq Biotech Index in 2005, but the second half of the year was brighter with stocks gaining 23.2 per cent, according to the Intersuisse Biotechnology Index.

Cancer drug developer Novogen (ASX:NRT, NASDAQ:NVGN) has concluded its investigation into the reasons why there was an overwhelming majority of proxies against the company's remuneration report.

Marshall Edwards, the US-based subsidiary of Australian cancer drug developer Novogen (ASX:NRT, NASDAQ:NVGN), has begun a phase Ib/IIa trial of Novogen's investigational chemotherapy re-sensitising drug phenoxodiol.